Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets

Summary

The study is to compare the rate and extent of absorption of a generic formulation with that of a reference for mulation when given as equal labeled dose. The study will be randomized, open-label, single dose, two way crossover design with two-period, two-treatment and two-sequence under fasting condition and at least 14 days washout period between the doses.

Timeline

Start

2024-09-03

Primary completion

2024-10-01

Completion

2024-10-15

Drugs

Indications

No indication recorded.